In a 54-year-old woman with chronic low back pain who has exhausted non‑opioid treatments, when should the opioid risk tool (e.g., SOAPP) be used and how should its results guide opioid prescribing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Opioid Risk Assessment Tools in Chronic Low Back Pain

Before initiating opioid therapy in your 54-year-old patient with chronic low back pain, you should use a validated risk assessment tool like the SOAPP-R (Screener and Opioid Assessment for Patients with Pain-Revised) at baseline, and the results should directly inform whether to prescribe opioids at all, what dose to start, and how frequently to monitor.

When to Use Risk Assessment Tools

Risk assessment must occur before starting opioid therapy and should be integrated into your initial evaluation 1. The CDC guidelines explicitly recommend evaluating risk factors for opioid-related harms before initiating therapy and incorporating risk mitigation strategies into your management plan 1. This is not optional—it's a core component of safe opioid prescribing.

For your patient specifically:

  • Timing: Administer the SOAPP-R during the visit when you're considering opioid initiation
  • Context: This comes after confirming that non-opioid treatments (NSAIDs, acetaminophen, physical therapy, cognitive behavioral therapy) have been exhausted 2, 3
  • Integration: Use alongside checking your state's Prescription Drug Monitoring Program (PDMP) and baseline urine drug screening 1

How Results Should Guide Prescribing

High-Risk Patients (SOAPP-R ≥18)

If your patient scores ≥18 on the SOAPP-R 4:

Consider NOT prescribing opioids at all. The evidence shows opioids provide only modest short-term benefits for chronic low back pain with questionable long-term efficacy 2, 5, and high-risk patients face substantially increased risks of aberrant drug-related behaviors, addiction, and overdose 2, 1.

If you still proceed with opioids despite high risk:

  • Start with the absolute lowest dose of immediate-release (not extended-release) opioids 1
  • Keep doses well below 50 MME/day 1
  • Schedule follow-up within 1-2 weeks (not the standard 1-4 weeks) 1
  • Check PDMP at every prescription 1
  • Conduct urine drug testing monthly initially, then at least every 3 months 1
  • Prescribe naloxone for overdose reversal 1
  • Set a time-limited trial (e.g., 4-6 weeks) with predetermined functional goals 2, 1

Low-Risk Patients (SOAPP-R <18)

Even in lower-risk patients 4:

  • Start immediate-release opioids at the lowest effective dose 1
  • Avoid doses ≥50 MME/day; carefully justify any decision to approach 90 MME/day 1
  • Follow-up within 1-4 weeks to reassess benefits versus harms 1
  • Check PDMP at initiation and periodically (ranging from every prescription to every 3 months) 1
  • Urine drug testing before starting and at least annually 1
  • Reassess every 3 months whether benefits outweigh harms 1

Specific Risk Factors to Identify

The SOAPP-R assesses multiple domains 6, 4, but pay particular attention to:

  • History of substance abuse (alcohol, illicit drugs, prescription medications)
  • Mental health conditions (depression, anxiety)—these predict higher opioid prescribing 7
  • Legal problems related to substance use
  • Medication-seeking behaviors or craving patterns
  • Heavy tobacco use
  • Younger age (associated with higher risk) 8
  • Concurrent benzodiazepine use (absolute contraindication to combine with opioids) 1

Critical Caveats

The SOAPP-R has limitations: It shows good sensitivity (0.81) but modest specificity (0.68) 4, meaning some patients will be incorrectly flagged as high-risk. However, given the serious harms of opioid misuse versus the modest benefits for chronic low back pain 2, 5, err on the side of caution.

Risk assessment is ongoing, not one-time: Even low-risk patients can develop problems. Continue monitoring with tools like the Current Opioid Misuse Measure (COMM) at follow-up visits 9.

Risk tools don't replace clinical judgment: If your patient has exhausted truly comprehensive non-opioid therapy (including supervised exercise, cognitive behavioral therapy, and potentially multidisciplinary pain programs 3), and shows clear functional impairment, the risk assessment helps you prescribe more safely—but the fundamental question remains whether opioids are appropriate at all for chronic low back pain given their limited long-term efficacy 2, 5.

Document everything: Record the SOAPP-R score, your risk-benefit discussion with the patient, realistic treatment goals, and your plan for discontinuation if benefits don't materialize 1.

References

Guideline

use and misuse of opioids in chronic pain.

Annual Review of Medicine, 2018

Research

Frequency and predictors of risk of non-medical opioid use among patients with cancer in a specialized outpatient palliative care clinic.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.